EBCC 2024 | MR-guided adaptive partial breast radiotherapy in low-risk breast cancer

Claire Van Vliet, MD, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, highlights findings of a Phase II study of magnetic resonance (MR)-guided adaptive partial breast radiotherapy in low-risk breast cancer. The treatment showed sustained low rates of toxicity. Fatigue was the most common side effect, which was mostly seen at grade I/II. The minimally invasive procedure had good cosmetic outcomes, with most patients reportedly satisfied. This interview took place at the 14th European Breast Cancer Conference (EBCC) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.